Miltefosine

• CAT Number: A000585
• CAS Number: 58066-85-6
• Molecular Formula: C21H46NO4P
• Molecular Weight: 407.6
• Purity: ≥95%
• Target: Akt
• Solubility: Limited solubility
• Storage: Store at -20C
• Related CAS: 93597-88-7
• IUPAC Name: hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
• InChI: InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3
• InChIKey: PQLXHQMOHUQAKB-UHFFFAOYSA-N
• SMILES: CCCCCCCCCCCCCCCCOP(OCC[N+](C)(C)C)([O-])=O

Miltefosine(CAS 58066-85-6)  is an orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity, mainly used to treat leishmaniasis and free-living amoeba infections such as Naegleria fowleri. It may be used together with liposomal amphotericin B or paromomycin.

Overview of Clinical Research

Miltefosine is a signal transduction pathway inhibitor. It received the orphan drug status for Granulomatous amebic encephalitis in USA in 2017.

Reference

1: Reinhardt M, Heyl P, Amelung F, Berger MR. Effect of miltefosine on transplanted methylnitrosourea-induced mammary carcinoma growing in Fischer 344 rats. Arzneimittelforschung. 1992 Oct;42(10):1239-42. PubMed PMID: 1282010.
2: Verweij J, Planting A, van der Burg M, Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol. 1992;118(8):606-8. PubMed PMID: 1325463.
3: Eibl H, Engel J. Synthesis of hexadecylphosphocholine (miltefosine). Prog Exp Tumor Res. 1992;34:1-5. PubMed PMID: 1438793.
4: Hilgard P. New pharmaceuticals: miltefosine. Anticancer Drugs. 1990 Dec;1(2):185. PubMed PMID: 2131052.